Codivir, a medicine used to treat HIV that also has a direct antiviral effect on coronavirus, was featured in an article published in the Jerusalem Post. The goal, according to Zyon Ayni, CEO and founder of Code Pharma, is to complete the study in three to six months and then file for emergency use authorization of the drug as soon as possible.
Zyon Ayni said: “The safety profile of the drug was very good. There were no significant side effects from the treatment itself. One hospital there started administering it to COVID-19 patients, too, and they got completely better – some in hours and some in days. The world is in need of an antiviral medication against COVID”.
